Malignant pertussis in infants: factors associated with mortality in a multicenter cohort study.
Hyperleukocytosis
Leukodepletion
Malignant pertussis
Pediatric intensive care
Risk factors of death
Journal
Annals of intensive care
ISSN: 2110-5820
Titre abrégé: Ann Intensive Care
Pays: Germany
ID NLM: 101562873
Informations de publication
Date de publication:
07 May 2021
07 May 2021
Historique:
received:
09
10
2020
accepted:
20
04
2021
entrez:
7
5
2021
pubmed:
8
5
2021
medline:
8
5
2021
Statut:
epublish
Résumé
Malignant pertussis (MP) affects young infants and is characterized by respiratory distress, perpetual tachycardia and hyperleukocytosis up to 50 G/l, leading to multiple organ failure and death in 75% of cases. Leukodepletion may improve prognosis. A therapeutic strategy based on leukodepletion and extracorporeal life support (ECLS) according to different thresholds of leucocytes has been proposed by Rowlands and colleagues. We aimed at identifying factors associated with death and assess whether the respect of the Rowlands' strategy is associated with survival. We reviewed all MP infants hospitalized in eight French pediatric intensive care units from January 2008 to November 2013. All infants younger than 3 months of age, admitted for respiratory distress with a diagnosis of pertussis and WBC count ≥ 50 G/l were recorded. Evolution of WBC was analyzed and an optimal threshold for WBC growth was obtained using the ROC-curve method. Clinical and biological characteristics of survivors and non-survivors were compared. Therapeutic management (leukodepletion and/or ECLS) was retrospectively assessed for compliance with Rowlands' algorithm (indication and timing of specific treatments). Twenty-three infants were included. Nine of 23 (40%) died: they presented more frequently cardiovascular failure (100% vs 36%, p = 0.003) and pulmonary hypertension (PHT; 100% vs 29%, p = 0.002) than survivors and the median [IQR] WBC growth was significantly faster among them (21.3 [9.7-28] G/l/day vs 5.9 [3.0-6.8] G/l/day, p = 0.007). WBC growth rate > 12 G/l/day and lymphocyte/neutrophil ratio < 1 were significantly associated with death (p = 0.001 and p = 0.003, respectively). Ten infants (43%) underwent leukodepletion, and seven (30%) underwent ECLS. Management following Rowlands' strategy was associated with survival (100% vs 0%; p < 0.001, relative risk of death = 0.18, 95%-CI [0.05-0.64]). A fast leukocyte growth and leukocytosis with neutrophil predominance during acute pertussis infection were associated with death. These findings should prompt clinicians to closely monitor white blood cells in order to early identify infants at risk of fatal outcome during the course of malignant pertussis. Such an early signal in infants at high risk of death would increase feasibility of compliant care to Rowlands' strategy, with the expectation of a better survival.
Sections du résumé
BACKGROUND
BACKGROUND
Malignant pertussis (MP) affects young infants and is characterized by respiratory distress, perpetual tachycardia and hyperleukocytosis up to 50 G/l, leading to multiple organ failure and death in 75% of cases. Leukodepletion may improve prognosis. A therapeutic strategy based on leukodepletion and extracorporeal life support (ECLS) according to different thresholds of leucocytes has been proposed by Rowlands and colleagues. We aimed at identifying factors associated with death and assess whether the respect of the Rowlands' strategy is associated with survival.
METHODS
METHODS
We reviewed all MP infants hospitalized in eight French pediatric intensive care units from January 2008 to November 2013. All infants younger than 3 months of age, admitted for respiratory distress with a diagnosis of pertussis and WBC count ≥ 50 G/l were recorded. Evolution of WBC was analyzed and an optimal threshold for WBC growth was obtained using the ROC-curve method. Clinical and biological characteristics of survivors and non-survivors were compared. Therapeutic management (leukodepletion and/or ECLS) was retrospectively assessed for compliance with Rowlands' algorithm (indication and timing of specific treatments).
RESULTS
RESULTS
Twenty-three infants were included. Nine of 23 (40%) died: they presented more frequently cardiovascular failure (100% vs 36%, p = 0.003) and pulmonary hypertension (PHT; 100% vs 29%, p = 0.002) than survivors and the median [IQR] WBC growth was significantly faster among them (21.3 [9.7-28] G/l/day vs 5.9 [3.0-6.8] G/l/day, p = 0.007). WBC growth rate > 12 G/l/day and lymphocyte/neutrophil ratio < 1 were significantly associated with death (p = 0.001 and p = 0.003, respectively). Ten infants (43%) underwent leukodepletion, and seven (30%) underwent ECLS. Management following Rowlands' strategy was associated with survival (100% vs 0%; p < 0.001, relative risk of death = 0.18, 95%-CI [0.05-0.64]).
CONCLUSIONS
CONCLUSIONS
A fast leukocyte growth and leukocytosis with neutrophil predominance during acute pertussis infection were associated with death. These findings should prompt clinicians to closely monitor white blood cells in order to early identify infants at risk of fatal outcome during the course of malignant pertussis. Such an early signal in infants at high risk of death would increase feasibility of compliant care to Rowlands' strategy, with the expectation of a better survival.
Identifiants
pubmed: 33961197
doi: 10.1186/s13613-021-00856-y
pii: 10.1186/s13613-021-00856-y
pmc: PMC8105476
doi:
Types de publication
Journal Article
Langues
eng
Pagination
70Références
Intensive Care Med. 2000 Oct;26(10):1512-4
pubmed: 11126265
Chest. 2007 Aug;132(2):410-7
pubmed: 17573487
Crit Care Med. 1993 Nov;21(11):1791-4
pubmed: 8222700
Rev Chilena Infectol. 2012 Jun;29(3):290-306
pubmed: 23096468
Pediatrics. 2010 Oct;126(4):e816-27
pubmed: 20819895
Hematology Am Soc Hematol Educ Program. 2012;2012:475-84
pubmed: 23233622
Pediatrics. 2003 Dec;112(6 Pt 1):1274-8
pubmed: 14654596
J Pediatr. 2003 Nov;143(5):576-81
pubmed: 14615725
Medicine (Baltimore). 2017 Dec;96(48):e8823
pubmed: 29310361
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
Transfusion. 2014 Jun;54(6):1630-3
pubmed: 24330004
Arch Pediatr. 2001 Sep;8 Suppl 4:705s-711s
pubmed: 11582916
Pediatr Crit Care Med. 2017 Jan;18(1):e42-e47
pubmed: 27811532
Pediatr Infect Dis J. 2013 Jun;32(6):698-9
pubmed: 23407101
Intensive Care Med. 1998 Oct;24(10):1089-92
pubmed: 9840245
J Pediatric Infect Dis Soc. 2013 Mar;2(1):1-6
pubmed: 26619437
Arch Fr Pediatr. 1956;13(8):880-8
pubmed: 13382369
Pediatr Pulmonol. 2009 Oct;44(10):970-80
pubmed: 19725100
Pediatr Crit Care Med. 2018 Mar;19(3):254-261
pubmed: 29319632
Pediatr Crit Care Med. 2005 Jan;6(1):2-8
pubmed: 15636651
Pediatr Crit Care Med. 2007 May;8(3):207-11
pubmed: 17417115
Pediatr Pulmonol. 2003 Oct;36(4):310-5
pubmed: 12950044
Pediatr Infect Dis J. 2003 Jul;22(7):628-34
pubmed: 12867839
Pediatr Crit Care Med. 2013 May;14(4):356-65
pubmed: 23548960
Pediatrics. 2004 Aug;114(2):e264-6
pubmed: 15286267
J Paediatr Child Health. 2017 Mar;53(3):257-262
pubmed: 28058755
Comput Math Methods Med. 2017;2017:3762651
pubmed: 28642804
Clin Infect Dis. 2008 Aug 1;47(3):328-38
pubmed: 18558873